Incidence and economic burden of suspected adverse events and adverse event monitoring during AF therapy

References

• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5
   PubMed Web of Science ®Google Scholar
• Wu EQ, Birnbaum HG, Mareva M, et al. Economic burden and co-morbidities of atrial fibrillation in a privately insured population. Curr Med Res Opin 2005;21:1693-9
   PubMed Web of Science ®Google Scholar
• Coyne KS, Paramore C, Grandy S, et al. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health 2006;9:348-56
   PubMed Web of Science ®Google Scholar
• Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e257-354
   PubMed Web of Science ®Google Scholar
• Product Information: Betapace™, sotalol hydrochloride. Bayer HealthCare Pharmaceuticals Inc., NJ, US. PI revised April 2007
   Google Scholar
• Product Information: Cordarone®, amiodarone hydrochloride. Wyeth Laboratories, PA, US. PI revised August 20, 2001
   Google Scholar
• Product Information: Rythmol®, propafenone hydrochloride. Reliant Pharmaceuticals, Inc., NJ, US
   Google Scholar
• Product Information: Lopressor®, metoprolol tartrate. Novartis Pharmaceuticals Corporation, NY, US. PI revised February, 2008
   Google Scholar
• Product Information: Lanoxin®, digoxin. GlaxoSmithKline, NC, US. PI revised November, 2006
   Google Scholar
• Product Information: Cardizem®, diltiazem hydrochloride. Biovail Laboratories International SLR, ON, US. PI revised September, 2007
   Google Scholar
• Kim MH, Klingman D, Lin J, et al. Cost of hospital admission for antiarrhythmic drug initiation in atrial fibrillation. Ann Pharmacother 2009;43:840-8
   PubMed Web of Science ®Google Scholar
• Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000;342:913-20
   PubMed Web of Science ®Google Scholar
• Al-Khatib SM, LaPointe NM, Curtis LH, et al. Outpatient prescribing of antiarrhythmic drugs from 1995 to 2000. Am J Cardiol 2003;91:91-4
   PubMed Web of Science ®Google Scholar
• Singh BN Amiodarone: a multifaceted antiarrhythmic drug. Curr Cardiol Rep 2006;8:349-55
   PubMedGoogle Scholar
• Siddoway LA Amiodarone: guidelines for use and monitoring. Am Fam Physician 2003;68:2189-96
   PubMed Web of Science ®Google Scholar
• Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33
   PubMed Web of Science ®Google Scholar
• Marshall DA, Levy AR, Vidaillet H, et al. Cost-effectiveness of rhythm versus rate control in atrial fibrillation. Ann Intern Med 2004;141:653-61
   PubMed Web of Science ®Google Scholar
• Hagens VE, Vermeulen KM, TenVergert EM, et al. Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation – results from the RAte Control versus Electrical cardioversion (RACE) study. Eur Heart J 2004;25:1542-9
   PubMed Web of Science ®Google Scholar
• Pietrasik A, Kosior DA, Niewada M, et al. The cost comparison of rhythm and rate control strategies in persistent atrial fibrillation. Int J Cardiol 2007;118:21-7
   PubMed Web of Science ®Google Scholar
• Blumentals WA, Gomez-Caminero A, Joo S, et al. Should erectile dysfunction be considered as a marker for acute myocardial infarction? Results from a retrospective cohort study. Int J Impot Res 2004;16:350-3
   PubMed Web of Science ®Google Scholar
• Kessler RC, Cantrell CR, Berglund P, et al. The effects of copayments on medication adherence during the first two years of prescription drug treatment. J Occup Environ Med 2007;49:597-609
   PubMed Web of Science ®Google Scholar
• Kim MH, Lin J, Hussein M, et al. Incidence and temporal pattern of hospital readmissions for patients with atrial fibrillation. Curr Med Res Opin 2009;25:1215-20
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• Burgess C, Blaikie A, Ingham T, et al. Monitoring the use of amiodarone: compliance with guidelines. Intern Med J 2006;36:289-93
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation – Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000;356:1789-94
   PubMed Web of Science ®Google Scholar
• Naccarelli GV, Wolbrette DL, Khan M, et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol 2003;91:15D-26D
   PubMed Web of Science ®Google Scholar
• Van Gelder IC, Wyse DG, Chandler ML, et al. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace 2006;8:935-42
   PubMed Web of Science ®Google Scholar